Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation
CD117
Hematopoietic stem cell
DOI:
10.1038/s41467-018-08201-x
Publication Date:
2019-02-06T11:04:47Z
AUTHORS (16)
ABSTRACT
Abstract Hematopoietic stem cell transplantation (HSCT) is a curative therapy for blood and immune diseases with potential many settings beyond current standard-of-care. Broad HSCT application currently precluded largely due to morbidity mortality associated genotoxic irradiation or chemotherapy conditioning. Here we show that single dose of CD117-antibody-drug-conjugate (CD117-ADC) saporin leads > 99% depletion host HSCs, enabling rapid efficient donor hematopoietic engraftment. Importantly, CD117-ADC selectively targets cells yet does not cause clinically significant side-effects. Blood counts function are preserved following treatment, effective responses by recipients both viral fungal challenges. These results suggest CD117-ADC-mediated pre-treatment could serve as non-myeloablative conditioning strategy the treatment wide range non-malignant malignant diseases, might be especially suited gene editing in which preservation immunity desired.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (26)
CITATIONS (158)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....